Ascendis Pharma announced the expiration of the regulatory waiting period for its collaboration agreement with Novo Nordisk, ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

Bad news for Novo Nordisk (NVO 4.37%) Friday was good news for Eli Lilly (LLY 3.71%) and Viking Therapeutics (VKTX 0.17%), its two main rivals in the field of weight loss drugs. This morning ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

Novo Nordisk (NVO) and Eli Lilly (LLY), the undisputed leaders in the global obesity drug market, saw their stocks heading in opposite directions later this week after the former disappointed ...

With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in stock price. Despite the miss, CagriSema's results are competitive ...

Shares in Ozempic maker Novo Nordisk tumbled after an experimental anti-obesity shot fell short of expectations. The shares fell more than 20% in Copenhagen, closing at their lowest since August 2023.

This agreement grants Novo Nordisk an exclusive license to develop and market products targeting obesity and type 2 diabetes, with Ascendis set to receive a $100 million milestone payment ...